For example, similar to the antitumor effect of CA4P, bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, inhibits angiogenesis in NSCLC patients. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.